We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
BIO-RAD LABORATORIES

Siemens Healthineers - Laboratory Diagnostics

Provides advanced laboratory diagnostics solutions for the medical industry read more Featured Products: More products

Download Mobile App





Siemens Presents Latest Innovations and Trends in Clinical Diagnostics and POC Testing

By LabMedica International staff writers
Posted on 21 May 2023
Print article
Image: The Atellica HEMA 570 and 580 Analyzers (Photo courtesy of Siemens Healthineers)
Image: The Atellica HEMA 570 and 580 Analyzers (Photo courtesy of Siemens Healthineers)

Siemens Healthineers (Erlangen, Germany) is presenting its newest innovations at WorldLab–EuroMedLab Roma 2023 that aim to help deliver high-value care, and confidently provide the answers expected by clinicians and patients. A team of company experts is demonstrating innovations and trends in clinical diagnostics and point-of-care testing at the industry event.

On display at the Siemens booth are the company’s two new solutions for high-volume hematology testing, the Atellica HEMA 570 Analyzer and the Atellica HEMA 580 Analyzer. Both hematology analyzers offer integrated automation and intelligence to eliminate barriers that hamper workflow efficiency and deliver faster patient results. The Atellica HEMA 570 and Atellica HEMA 580 Analyzers have a throughput of up to 120 tests per hour and feature user-friendly designs that significantly reduce time-consuming daily maintenance and support rapid reagent changes.

The Atellica HEMA 570 and Atellica HEMA 580 Analyzers adopt advanced data management capabilities to eliminate the expertise gap and empower staff of all skill levels during result interpretations. In order to save time and provide physicians with information more quickly, normal results that do not violate pre-established criteria are released directly into a laboratory information system using the analyzers' rules-based auto-validation capability. Abnormalities are flagged and coded on the basis of severity to provide a clear indication of which patient samples need closer attention from the technician. In case results require follow-up actions like dilutions or slide reviews, standardized guidance is displayed to ensure that staff performs the next steps in accordance with lab protocols.

"We hear from labs that they need agility, reliability, and speed," said Sharon Bracken, Head of Diagnostics, Siemens Healthineers. "The Atellica HEMA analyzers combine workflow improvements with demonstrated technology to bring hematology testing into the future. We're delivering the breakthroughs labs need to produce quality patient results faster."

Related Links:
Siemens Healthineers 

Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Magnetic Bead Separation Modules
MAG and HEATMAG
POCT Fluorescent Immunoassay Analyzer
FIA Go
Gold Member
ADAMTS-13 Protease Activity Test
ATS-13 Activity Assay

Print article

Channels

Clinical Chemistry

view channel
Image: The 3D printed miniature ionizer is a key component of a mass spectrometer (Photo courtesy of MIT)

3D Printed Point-Of-Care Mass Spectrometer Outperforms State-Of-The-Art Models

Mass spectrometry is a precise technique for identifying the chemical components of a sample and has significant potential for monitoring chronic illness health states, such as measuring hormone levels... Read more

Molecular Diagnostics

view channel
Image: Liquid biopsy could detect and monitor aggressive small cell lung cancer (Photo courtesy of Shutterstock)

Blood-Based Test Detects and Monitors Aggressive Small Cell Lung Cancer

Small cell lung cancer (SCLC) is a highly aggressive type of cancer known for its ability to metastasize. The behavior of tumors is largely governed by which genes are turned on, or transcribed, irrespective... Read more

Hematology

view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more

Immunology

view channel
Image: The groundbreaking treatment approach has shown promise in hard-to-treat cancers (Photo courtesy of 123RF)

Genetic Testing Combined With Personalized Drug Screening On Tumor Samples to Revolutionize Cancer Treatment

Cancer treatment typically adheres to a standard of care—established, statistically validated regimens that are effective for the majority of patients. However, the disease’s inherent variability means... Read more

Microbiology

view channel
Image: Microscope image showing human colorectal cancer tumor with Fusobacterium nucleatum stained in a red-purple color (Photo courtesy of Fred Hutch Cancer Center)

Mouth Bacteria Test Could Predict Colon Cancer Progression

Colon cancer, a relatively common but challenging disease to diagnose, requires confirmation through a colonoscopy or surgery. Recently, there has been a worrying increase in colon cancer rates among younger... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.